Advertisement
Screener

GLAUKOS Corp (GKOS) Research and Development in Process

2.8 / 5 stars · 68/120 Roast Me

GLAUKOS Corp Research and Development in Process

GLAUKOS Corp (GKOS) reported Research and Development in Process of $10.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-24.

Discontinued › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-24

  • GLAUKOS Corp research and development in process for the quarter ending 2022-12-31 was $0.00.
  • GLAUKOS Corp research and development in process for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
  • GLAUKOS Corp research and development in process for the quarter ending 2022-06-30 was $10.00M, a 100.00% increase year-over-year.
  • GLAUKOS Corp research and development in process for the quarter ending 2022-03-31 was $0.00.
  • GLAUKOS Corp research and development in process for fiscal 2022 was $10.00M, a 0.00% change from fiscal 2021.
  • GLAUKOS Corp research and development in process for fiscal 2021 was $10.00M.
  • GLAUKOS Corp research and development in process for fiscal 2019 was $3.75M.
  • GLAUKOS Corp research and development in process for fiscal 2017 was $5.32M.
Period endResearch and Development in Process 3 monthResearch and Development in Process 6 monthResearch and Development in Process 9 monthResearch and Development in Process 12 month
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24
$0.00
derived: sum of 2 quarters · filed 2023-02-24
$10.00M
derived: sum of 3 quarters · filed 2023-02-24
$10.00M
10-K · filed 2023-02-24
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04
$10.00M
derived: sum of 2 quarters · filed 2023-02-24
$10.00M
10-Q · filed 2022-11-04
$10.00M
derived: sum of 4 quarters · filed 2023-02-24
2022-06-30$10.00M
10-K · filed 2023-02-24
$10.00M
10-Q · filed 2022-08-05
$10.00M
derived: sum of 3 quarters · filed 2023-02-24
$15.00M
derived: sum of 4 quarters · filed 2023-02-24
2022-03-31$0.00
derived: 10-K 12 month − 3 quarters · filed 2023-02-24
$0.00
derived: sum of 2 quarters · filed 2023-02-24
$5.00M
derived: sum of 3 quarters · filed 2023-02-24
$10.00M
derived: sum of 4 quarters · filed 2023-02-24
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24
$5.00M
derived: sum of 2 quarters · filed 2023-02-24
$10.00M
derived: sum of 3 quarters · filed 2023-02-24
$10.00M
10-K · filed 2023-02-24
2021-09-30$5.00M
10-K · filed 2023-02-24
$10.00M
derived: sum of 2 quarters · filed 2023-02-24
$10.00M
10-Q · filed 2022-11-04
2021-06-30$5.00M
10-K · filed 2023-02-24
$5.00M
10-Q · filed 2022-08-05
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$1.50M
derived: sum of 2 quarters · filed 2022-02-28
$3.75M
derived: sum of 3 quarters · filed 2022-02-28
$3.75M
10-K · filed 2022-02-28
2019-09-30$1.50M
10-K · filed 2021-03-01
$3.75M
derived: sum of 2 quarters · filed 2021-03-01
$3.75M
10-Q · filed 2020-11-05
2019-06-30$2.25M
10-K · filed 2021-03-01
$2.25M
10-Q · filed 2020-08-07
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$0.00
derived: sum of 2 quarters · filed 2020-03-02
$5.32M
derived: sum of 3 quarters · filed 2020-03-02
$5.32M
10-K · filed 2020-03-02
2017-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$5.32M
derived: sum of 2 quarters · filed 2019-02-28
$5.32M
10-Q · filed 2018-11-07
2017-06-30$5.32M
10-K · filed 2019-02-28
$5.32M
10-Q · filed 2018-08-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSULET CORP (PODD)United States$9.420B28.12
GLOBUS MEDICAL INC (GMED)United States$9.977B20.03
BAXTER INTERNATIONAL INC (BAX)United States$12.139B-10.35
MiniMed Group, Inc. (MMED)United States$5.748B-16.85
Penumbra Inc (PEN)United States$12.596B77.33
MERIT MEDICAL SYSTEMS INC (MMSI)United States$5.212B28.44
TELEFLEX INC (TFX)United States$5.093B-5.44
HAEMONETICS CORP (HAE)United States$4.821B36.52
Heartflow, Inc. (HTFL)United States$4.225B
ICU MEDICAL INC/DE (ICUI)United States$4.153B18.85